[New oral anticoagulants in the prevention of thromboembolic complications in atrial fibrillation - a single-center experience.]

[New oral anticoagulants in the prevention of thromboembolic complications in atrial fibrillation - a single-center experience.] Kardiol Pol. 2014 Sep 2; Authors: Gorczyca-Michta I, Wożakowska-Kapłon B Abstract Introduction:The prevention of thromboembolic complications in patients with atrial fibrillation(AF) takes priority in this group. In light of applicable guidelines, thesignificance of vitamin K antagonists (VKA) in stroke prevention decreased in favorofan ever more important role of new oral anticoagulants (nOAC). Theobjectives of this study are: theevaluation of the frequency of nOAC recommendations, the comparison between thepopulation of patients treatedwith VKA and those receiving nOAC, as well as theidentification of factors predisposing to the administration of nOAC to AF patients ondischarge.Methodsand materials: A single-center prospective study was carried out on the basisof themedical documentation of 550 patients who were diagnosed with non-valvular AF anddischarged from the cardiology clinic in the period from September 2012 toAugust 2013 (12 months after the publication of thecurrent applicable guidelines).Outcomes:In the group of 550 patients with AF, OAC in stroke prevention was administered to463 patients (84.2%), whereas VKA was recommended for 373 subjects(80.6% of patients treated with OAC) on discharge. NOAC received 90 patients(19.4% subjects treated with OAC). In the group of patients receiving nOAC,da...
Source: Polish Heart Journal - Category: Cardiology Authors: Tags: Kardiol Pol Source Type: research